Clinical trials
Active, not recruiting Phase 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2016 | 4 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 18 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Center for International Blood and Marrow Transplant Research | 2 |
| M.D. Anderson Cancer Center | 2 |
| St. Jude Children's Research Hospital | 2 |
| Baylor College of Medicine | 1 |
| Centre Leon Berard | 1 |
| European LeukemiaNet | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Groupe Francophone des Myelodysplasies | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 18 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 |
| Leukemia, Myeloid, Acute | 6 |
| Myelodysplastic Syndromes | 6 |
| Hodgkin Disease | 3 |
| Leukemia, Biphenotypic, Acute | 3 |
| Leukemia, Myeloid | 3 |
| Leukemia, Myeloid, Chronic-Phase | 3 |
| Lymphoma, Non-Hodgkin | 3 |
| Lymphoproliferative Disorders | 3 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.